SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending following the federal reclassification of cannabis to Schedule III, a move widely seen as removing significant tax burdens and unlocking substantial profitability for the cannabis industry. The community views $WEEDCOIN as a leading cultural and financial proxy on Solana for this "green revolution," actively discussing its role in disrupting traditional pharmaceuticals.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending amidst intense community discussion and speculation regarding an imminent joint press release, expected by year-end, announcing a potentially transformative partnership with a major player in government or military AI. Despite ongoing debates among technical analysts about bullish and bearish chart patterns and some skepticism about past predictions, investors are keenly focused on this catalyst to drive the company's valuation in the booming AI data training sector.

Nexa Resources SA engages in the production of zinc in Latin America. It operates through the Mining and Smelting segments. The Mining segment comprises of mines located in Peru and Brazil, which includes mineral exploration activities and the production of zinc, copper, and lead concentrates. The Smelting segment consists of facilities that recover and produce metallic zinc, zinc oxide, and by-products. The company was founded on February 26, 2014 and is headquartered in Luxembourg.

Nexa Resources S.A.

Nexa Resources is trending due to a strategic agreement to divest certain Namibian prospecting licenses, generating buzz around its asset optimization efforts. The community is also reacting positively to its solid operational performance, leading to discussions about the stock's undervaluation and potential for a significant upward move, particularly driven by its exposure to base metals and the "silver story."

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL CRYPTO) is a focal point of discussion following its recent integration with Alchemy Pay for fiat on-ramps and upcoming listing on a major Chinese exchange, with some anticipating a significant upward movement. Community sentiment is sharply polarized: supporters emphasize its zero-fee stablecoin transfers and Bitcoin network utility, while detractors express deep skepticism regarding its substantial price decline since launch, concerns about token unlocks, and questions surrounding team communication. This dynamic creates a volatile but actively watched situation for the stablecoin-focused Layer 1 project.

Inseego Corp. engages in the business of communication equipment. Its products include mobile hotspots, industrial gateways and routers, home and enterprise routers, industrial USB modems, and telematics and mobile tracking hardware devices. Its SaaS platforms include Ctrack, an asset tracking and management solution that delivers business intelligence for fleets used in various verticals, including aviation, construction, government, and transport, and Device Management Solutions, a hosted subscription management platform. The company was founded on April 26, 1996 and is headquartered in San Diego, CA.

Inseego Corp

Inseego is actively discussed following its strategic shift to focus on 5G FWA, highlighted by significant debt reduction, new executive leadership, and positive analyst sentiment including an upgrade to "Buy." While many investors are optimistic about the company's turnaround and new product launches, others remain cautious, reflecting on past volatility and recent price fluctuations linked to the misinterpreted impact of its Telematics business sale.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending due to recent market volatility, experiencing a significant pullback following reports of major hyperscalers adopting competitor networking solutions despite the company delivering a strong earnings beat and reaffirming robust AI revenue targets. This has fueled lively community discussion, with many viewing the dip as an overreaction and a prime buying opportunity for a critical AI networking and cloud infrastructure provider, while others remain cautious about competitive dynamics.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

Flora Growth Corp. is trending amid its rebrand to "ZeroStack" and a strategic pivot to decentralized AI and a crypto treasury, reportedly holding over $100M in 0G tokens against a very low market capitalization. The community is buzzing about a potential short squeeze fueled by the extremely low share float, with many anticipating substantial price appreciation. Conversely, a significant portion of investors remains cautious, viewing the play as a high-risk pump given the associated token's volatility and the stock's historical performance.

Theoriq is a decentralized Web3 project that focuses on creating an ecosystem of autonomous AI agents that can collaborate in multi-agent swarms to perform complex tasks. Unlike traditional AI, these agents work together, validate each other’s outputs, and operate on-chain, making them especially useful for applications in DeFi, on-chain analytics, and automation.  The project combines AI intelligence with blockchain technology, enabling developers, users, and data providers to contribute, earn rewards, and participate in decentralized governance. Its goal is to democratize AI by creating a community-driven, secure, and scalable network where autonomous agents can execute tasks and generate value efficiently.

Theoriq

THQ Crypto is actively trending due to its recent listing on Coinbase, which has been followed by significant price declines, sparking intense community debate. While some investors are optimistic about its low circulation and potential for future exchange listings, many others are expressing frustration over substantial losses and questioning the viability of newly listed altcoins.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices (ADI) is trending following strong earnings performance and optimistic guidance, which signal a cyclical recovery in industrial and automotive markets. Analysts have responded with numerous price target raises, and the community is actively discussing ADI's position as a key beneficiary of the broader AI-driven semiconductor growth. Despite some notes of caution regarding valuation at current levels, prevailing sentiment points to continued bullish momentum and institutional interest.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is rapidly becoming a focal point as global demand for secure, non-Chinese tungsten supply intensifies, driven by China's recent export controls and tungsten's critical role in defense and technology. The community is buzzing about the company's strategic U.S. tungsten project acquisition, the nearing production at its Sangdong Mine, and robust analyst 'Buy' ratings. Many perceive ALM as an undervalued gem, anticipating significant upside from upcoming production milestones and potential partnerships with the U.S. government to bolster Western critical mineral supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...

Q4 Earnings Estimate for BCRX Issued By HC Wainwright

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the...

<ul class="summary-bullets"><li>BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated.</li><li>The company is also seeking approval for the drug’s use in the targeted age group in Europe, Japan, Canada, and other countries.&nbsp;</li><li>Orladeyo in capsule form is already FDA-approved for treating the disorder in those over 12 years of age.&nbsp;</li></ul>BioCryst Pharmaceuticals, Inc. (BCRX) has received approval from the U.S. Food and Drug Administration (FDA) for Orladeyo, an oral pellet formulation for the treatment of a rare genetic disorder in children.The approval comes after positive interim data from the APeX-P trial, which showed it is safe and well-tolerated and effectively reduces monthly HAE attacks in young children, the company said in a statement.BioCryst has also filed an application for the drug’s use with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. The company said it is exploring additional regulatory filings in other global territories, including Canada.Shares of <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> jumped over 4% on Friday morning at the time of writing.<h2 class="st-heading-2">Breakthrough Treatment For Young Children</h2>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and severe swelling in the skin, face, limbs, gut, and air pathways with potential life-threatening consequences.Orladeyo will become the first approved oral drug for the treatment of hereditary angioedema (HAE) in children aged 2 to 12, the company said. All other treatments for HAE in the market for the targeted demographic are currently administered intravenously or through injections.A capsule formulation of Orladeyo for treating HAE in children over 12 years and older adults received FDA approval in December 2020.“As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldn’t be more excited to bring this treatment option to these kids and their caregivers,” said Jon Stonehouse, chief executive officer of BioCryst.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, BCRX was among the top five trending stocks on Friday morning. The retail sentiment around BCRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1267/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_6_36_49_PM_png_130ee4212d.webp" alt="BCRX sentiment and message volume on Stocktwits. " width="1267" height="136"></figure>One Stocktwits user commended the FDA news.<stembedurl>https://stocktwits.com/Kiwiarse/message/638975638</stembedurl>Shares of BCRX are down over 3% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?

The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.

Equity

Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Hood River Capital Management LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 326.1% during the 2nd quarter, according to its most recent filing with...

JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

JPMorgan Chase & Co. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 48.7% during the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the business's stock in a transaction on Wednesday, December 3rd. The stock was sold at an...

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.